Method Profile
Compare matched tumor and organoid histone features and measure quisinostat-associated viability, RNA and acetylation changes.
Ex vivo evaluation of epigenetic pharmacology and patient-specific model fidelity in uveal melanoma.
ALI organoids established from five patients; histone and drug experiments used their stated subsets.
Matched tumor–organoid comparisons plus quisinostat, medium and DMSO conditions.
Source tissue
Fresh or cryopreserved surgically resected uveal melanoma.
Pharmacology
Quisinostat at 100 nM and 200 nM for 72 hours, with matched medium/DMSO controls.
Keep the five-patient establishment cohort, four matched histone pairs and two-tumor/eight-sample RNA drug experiment separate.
Matched tissue characterization combined with HDAC inhibitor treatment.
Five source patients; four matched tumor–organoid histone comparisons; two tumors/eight organoid samples for drug RNA profiling.
Matched source tumor tissue and medium/DMSO treatment controls.
Quisinostat increased several H3/H4 acetylation marks and changed gene expression; viability varied, while bright-field morphology showed little difference.
Air–liquid interface cultures preserved patient-specific features of uveal melanoma while showing culture-associated chromatin changes. Quisinostat altered histone acetylation and gene expression, with variable viability responses.
